Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis

Published:2023-08 Issue: Volume:131 Page:107324
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Mian Agrima^ORCID,Naqvi Syed Arsalan Ahmed,Ayaz Ahsan^ORCID,Husnain Muhammad,Aljama Mohammed A.,Mohyuddin Ghulam Rehman,Koehn Kelly,Mohan Meera,Bin Riaz Irbaz,Chakraborty Rajshekhar

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference39 articles.

1. Continued improvement in survival in multiple myeloma (MM) including high-risk patients;Nandakumar;JCO,2019

2. Multiple myeloma: the (r)evolution of current therapy and a glance into future;Gulla;Haematologica,2020

3. Monoclonal antibodies and antibody drug conjugates in multiple myeloma;Radocha;Cancers,2021

4. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council’s working party on leukaemia in adults;Cuzick;Br. J. Cancer,1987

5. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality;Costa;Br. J. Haematol.,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials;Scientific Reports;2024-01-05

2. Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews;Annals of Hematology;2023-11-08